September 23

FierceBiotech names Celsius Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

Cambridge, MA – September 23, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

“It is an incredible honor and we are humbled to be named a ‘Fierce 15’ company, which is a testament to both our promising single cell genomics-driven drug discovery approach as well as the hard work of our entire team,” said Tariq Kassum, M.D., chief executive officer of Celsius. “At Celsius, the combination of patient tissue samples, massive datasets, and sophisticated machine learning algorithms allows us, for the first time, to understand the specific cells driving disease. With this new level of clarity, our approach has fierce potential to deliver a powerful new class of precision medicines in autoimmune disease and cancer.”

“This year has seen unrivalled scientific talent in the early-stage life sciences world and it has been a pleasure to for us at FierceBiotech to speak to all 15 winners and hear their passion, progress and panache,” said Ben Adams, Senior Editor of FierceBiotech. “Each company brought something different, exciting and potentially life-changing for myriad patients around the world across a host of diseases and disorders, using cutting-edge science, top-notch teams and a drive to genuinely make the world a better place, despite the risks and challenges that, as ever in biotech, lay ahead.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. This is FierceBiotech’s 17th annual Fierce 15 selection.

About Celsius Therapeutics

Celsius Therapeutics is charting a new course of target and drug discovery by applying a systematic approach to single-cell sequencing of patient tissue, combining massive datasets, complex algorithms, and machine learning to discover first-in-class precision therapies with a transformative impact on the lives of patients with autoimmune diseases and cancer. Celsius was launched in 2018, is backed by Third Rock Ventures and GV (formerly Google Ventures), and is based in Cambridge, Mass. For more information, please visit www.celsiustx.com.

About FierceBiotech

FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 285,000 top biotech and pharma professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.

###

CONTACTS:

Rebecca Willumson
FierceBiotech
202-824-5050
rwillumson@questex.com

Katie Engleman
1AB
katie@1abmedia.com

CELSIUS THERAPEUTICS

399 Binney Street
Cambridge, MA 02139
857-776-7400

info@celsiustx.com